Rekombinant faktor VIIa ved post partum-blødning

Translated title of the contribution: Not Available

Anne Juul Wikkelsø, Jakob Stensballe


Recombinant factor VIIa (rFVIIa) has of April 2022 been approved by the European Medicines Agency for treatment of severe postpartum haemorrhage. The extended approval is based on one small open-label, non-blinded randomized trial of 84 women from 2015 showing reduced "second line" treatment, but also increased risk of thromboembolism. Systematic use of tranexamic acid and timely coagulation assessment with thromboelastography/rotational thromboelastometry are not applied. Danish and international societies recommend that rFVIIa is reserved as a last option in severe life-threatening cases of postpartum haemorrhage.

Translated title of the contributionNot Available
Original languageDanish
Article numberV07220423
JournalUgeskrift for Laeger
Issue number47
Publication statusPublished - 21 Nov 2022


Dive into the research topics of 'Not Available'. Together they form a unique fingerprint.

Cite this